{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:36Z","timestamp":1791232476872,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,8,20]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic and pharmacodynamic study of two formulations of pazopanib was performed in children with STS or other refractory solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      Pazopanib (tablet formulation) was administered once daily in 28-day cycles at four dose levels (275 to 600 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ) using the rolling-six design. Dose determination for a powder suspension was initiated at 50% of the maximum-tolerated dose (MTD) for the intact tablet. Ten patients with STS underwent dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) scanning at baseline and 15 \u00b1 2 days after initiation of pazopanib at the tablet MTD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fifty-three patients were enrolled; 51 were eligible (26 males; median age, 12.9 years; range, 3.8 to 23.9 years). Hematologic and nonhematologic toxicities were generally mild, with dose-limiting lipase, amylase, and ALT elevation, proteinuria, and hypertension. One patient with occult brain metastasis had grade 4 intracranial hemorrhage. The MTD was 450 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for tablet and 160 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for suspension. Steady-state trough concentrations were reached by day 15 and did not seem to be dose dependent. One patient each with hepatoblastoma or desmoplastic small round cell tumor achieved a partial response; eight patients had stable disease for \u2265 six cycles, seven of whom had sarcoma. All patients with evaluable DCE-MRI (n = 8) experienced decreases in tumor blood volume and permeability (P &lt; .01). Placental growth factor increased, whereas endoglin and soluble vascular endothelial growth factor receptor-2 decreased (P &lt; .01; n = 41).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pazopanib is well tolerated in children, with evidence of antiangiogenic effect and potential clinical benefit in pediatric sarcoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2012.47.0914","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T21:27:21Z","timestamp":1373923641000},"page":"3034-3043","source":"Crossref","is-referenced-by-count":154,"title":["Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report"],"prefix":"10.1200","volume":"31","author":[{"given":"Julia L.","family":"Glade Bender","sequence":"first","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Lee","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Baruchel","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Roberts","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan D.","family":"Voss","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wu","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte H.","family":"Ahern","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Ingle","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Harris","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda J.","family":"Weigel","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Blaney","sequence":"additional","affiliation":[{"name":"Julia L. Glade Bender and Alice Lee, Columbia University Medical Center, New York, NY; Joel M. Reid, Mayo Clinic Cancer Center, Rochester; Brenda J. Weigel, University of Minnesota Amplatz Children's Hospital, Minneapolis, MN; Timothy Roberts, Children's Hospital of Philadelphia, Philadelphia, PA; Stephan D. Voss, Boston Children's Hospital, Boston, MA; Charlotte H. Ahern and Susan M. Blaney, Texas Children's Cancer Center, Houston, TX; Ashish M. Ingle, Children's Oncology Group, Operations Center,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24016"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0078"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3223"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9725-2"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1542\/peds.114.2.S2.555"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.9674"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7712"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.158"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3658"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9230"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.1910370216"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2740"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.199"},{"key":"B17","unstructured":"R Aziz,  W Helms :  Votrient (pazopanib hydrochloride) tablets. Pharmacology review (NDA 22465) US Food and Drug Administration http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022465s000TOC.cfm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.15_suppl.3048"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn637"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds179"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2533"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.092"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.5655"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/9467"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.3545"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0237"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0148"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0078"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.47.0914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T18:52:16Z","timestamp":1653504736000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.47.0914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":29,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2013,8,20]]}},"alternative-id":["10.1200\/JCO.2012.47.0914"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.47.0914","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718036740.793483439","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]}}}